Environment-Wide Association Study of CKD

Jeonghwan Lee,1 Sohee Oh,2 Habyeong Kang3 Sunmi Kim4 Gowoon Lee,3 Lilin Li,4 Clara Tammy Kim,5 Jung Nam An,6 Yun Kyu Oh,1,4 Chun Soo Lim,1,4 Dong Ki Kim,4,7 Yon Su Kim,4,7 Kyungho Choi,3 and Jung Pyo Lee1,4

Abstract
Background and objectives Exposure to environmental chemicals has been recognized as one of the possible contributors to CKD. We aimed to identify environmental chemicals that are associated with CKD.

Design, setting, participants, & measurements We analyzed the data obtained from a total of 46,748 adults who participated in the National Health and Nutrition Examination Survey (1999–2016). Associations of chemicals measured in urine or blood (n=262) with albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g), reduced eGFR (<60 ml/min per 1.73 m²), and a composite of albuminuria or reduced eGFR were tested and validated using the environment-wide association study approach.

Results Among 262 environmental chemicals, seven (3%) chemicals showed significant associations with increased risk of albuminuria, reduced eGFR, or the composite outcome. These chemicals included metals and other chemicals that have not previously been associated with CKD. Serum and urine cotinines, blood 2,5-dimethylfuran (a volatile organic compound), and blood cadmium were associated with albuminuria. Blood lead and cadmium were associated with reduced eGFR. Blood cadmium and lead and three volatile compounds (blood 2,5-dimethylfuran, blood furan, and urinary phenylglyoxylic acid) were associated with the composite outcome. A total of 23 chemicals, including serum perfluorooctanoic acid, seven urinary metals, three urinary arsenics, urinary nitrate and thiocyanate, three urinary polycyclic aromatic hydrocarbons, and seven volatile organic compounds, were associated with lower risks of one or more manifestations of CKD.

Conclusions A number of chemicals were identified as potential risk factors for CKD among the general population.

Introduction
CKD is a global public health problem (1–3). The high prevalence of CKD worldwide cannot solely be explained by well known causes such as diabetes mellitus, hypertension, and GN. Recently, environmental factors have been recognized as important risk factors for the development and progression process of CKD (4,5). Production and use of consumer chemicals have significantly increased in recent decades (6), and chemicals can cause adverse outcomes for human health (7,8). Epidemiologic studies have revealed that at the levels of current exposure, many chemicals are closely associated with human diseases, including neurologic, endocrinologic, and neoplastic diseases (9,10).

Various genetic and environmental factors are suggested as potential risk factors for developing CKD (11). Indeed, several environmental chemicals, including melamine and heavy metals like lead or cadmium, have long been known to be risk factors for kidney injury and CKD (12). Recently, consumer chemicals such as phthalates and bisphenol A have also been reported to be associated with CKD not only among adults, but also among children or adolescents (13). In some populations, other environmental chemicals, including perfluoroalkyl acids, dioxins, polycyclic aromatic hydrocarbons, and polychlorinated biphenyls, have been suggested as a new risk factors for CKD (14,15). However, the associations of these environmental chemicals with kidney disease parameters and CKD are not consistent according to the time points, populations, and clinical circumstances. In addition, our knowledge on the role of chemicals in the cause of CKD is quite limited, considering the growing number of chemicals being introduced in the market and used in daily lives.

In this study, the associations between various environmental chemicals measured in the general United States population and the prevalence of CKD were evaluated. For this purpose, a genome-wide association study methodology was applied for environmental chemicals instead of various genetic phenotypes, i.e., an environment-wide association study (EWAS) (16). By utilizing EWAS, hundreds of bio-monitored chemicals were tested simultaneously for their association with CKD. The results of this study will help to identify a list of potential chemicals with significant association with CKD, which can be
Materials and Methods

Study Participants and Data Analyzed

We analyzed 46,748 adults (age ≥18 years) who participated in the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2016. Among 92,062 eligible participants, 38,714 young individuals (age <18 years) were initially excluded. In addition, 6600 participants who did not have data for either urinary albumin-to-creatinine ratio (ACR) or eGFR were finally excluded. This cross-sectional, observational cohort study was approved by the Institutional Review Board of Seoul National University Boramae Medical Center (approval number 07–2019–16). Information on the environmental chemicals as well as demographic and laboratory data were obtained from the NHANES database (https://www.cdc.gov/nchs/nhanes/index.htm; demographic, examination, questionnaire, and laboratory data set) in March 2019.

We defined hypertension as an average systolic BP of >140 mm Hg or diastolic BP of >90 mm Hg measured at least twice, history of hypertension, or currently taking antihypertensive medications. Diabetes mellitus was defined as fasting glucose level of ≥126 mg/dl, random glucose level of >200 mg/dl, or history of diabetes mellitus. Corrected serum creatinine levels were used in the survey of 1999–2000 and 2005–2006 (17,18). Serum and urine creatinine levels were measured using the Jaffe rate method (kinetic alkaline picrate) with calibration to an isotope dilution mass spectrometry reference method. Urinary albumin levels were measured using solid-phase fluorescent immunoassay. We calculated eGFR using the CKD Epidemiology Collaboration equations (19). Three CKD outcomes were assessed: albuminuria (urinary ACR ratio ≥30 mg/g), reduced eGFR (<60 ml/min per 1.73 m²), and a composite outcome of albuminuria or reduced eGFR.

Measured Chemicals

In NHANES, environmental chemicals were measured in randomly selected subsamples within specific age groups. Measurements of chemicals in serum were made in samples from participants aged ≥12 years. Urine chemicals were measured in a representative one-third subsample. In the discovery set, a total of 262 environmental (minimal number of observations above 500) chemicals were included in the analysis. These chemicals could be grouped as follows: blood acrylamide and glycidamide (n=2), serum and urinary cotinines (n=2), serum dioxins (dioxins, furans, coplanar polychlorinated biphenyls; n=59), blood metals (n=4), urinary metals (n=13), urinary arsenics (n=8), urinary polycyclic aromatic hydrocarbons (n=11), serum perfluoroalkyl and polyfluoroalkyl substances (n=12), urinary perchlorate/nitrate/thiocyanate (n=3), serum (n=9) and urinary pesticides (n=54), urinary pheno- nols (n=8), urinary phytoestrogens (n=6), urinary phthalates (n=15), and blood (n=29) and urinary volatile organic compounds (n=27). Information on environmental chemicals and measurement methods is given in Supplemental Appendices 1–3.

Statistical Analyses

The associations between various environmental chemicals measured in the urine or blood, and CKD were assessed by the EWAS approach proposed by Patel et al. for type 2 diabetes mellitus (16,20). EWAS refers to the association study of various exposomes and disease outcomes similarly to a genome-wide association study of SNPs and disease. In general, an EWAS of environmental chemicals for specific disease requires a multiple-cycle population study such as NHANES. An EWAS integrates the multiple survey results between chemical and disease using meta-analysis methods, and validates the results using other populations. Figure 1 presents the outline of the analytic approach used in this study.

We utilized the nine NHANES surveys (1999–2016) to analyze the association between environmental chemicals and CKD. The data sets from nine NHANES cycles (1999–2016) during the 18-year period were divided into the discovery and the validation sets. To reduce errors derived from chronological order, we assigned cycles in an alternate manner into the discovery set (1999–2000, 2003–2004, 2007–2008, 2011–2012, and 2015–2016) and validation set (2001–2002, 2005–2006, 2009–2010, and 2013–2014). In the discovery set, which is composed of data from the five NHANES cycles, the association between each environmental chemical and CKD was tested through survey weighted logistic regression with covariates of age, age-squared, sex, diabetes mellitus, hypertension, body mass index, race/ethnicity, smoking, and socioeconomic status. Family poverty-to-income ratio as a continuous variable was used for socioeconomic status adjustment. Considering the wide range of ages among NHANES participants, we added the age-squared term as a covariate to model the nonlinear effect of differing ages on disease outcomes. Imputation of missing values was not considered. The appropriate sample weights of the smallest subpopulation among variables were selected and adjusted among weights of mobile examination center or subsample weights of each chemicals (21). Then, the estimates from the five NHANES cycles in the discovery set were combined to obtain the meta-analytical results of the combined association and P values. Random-effects models were applied in the meta-analysis. To correct for multiple comparisons, we applied the false discovery rate in the meta-analysis. False discovery rate is one of the correction methods in multiple comparisons and is known to be less conservative compared with other correction approaches (22,23).

Heavy metal–induced nephropathy is known to share the common pathologic pathway of oxidative stress, and interaction and synergistic effects between heavy metals were recently reported (24,25). Interactions between significant heavy metal chemicals were tested with integration of interaction variable into each logistic regression from nine NHANES cycles. Pearson correlations between validated chemicals were summarized using correlation matrix (R library, corrplot). Environmental chemicals with false discovery rate <1% were considered as potential risk factors for CKD. Potential risk factors of environmental chemical for CKD identified in the discovery set were tested in the validation set, which is composed of the four NHANES cycles. P<0.05 was considered a significant cut-off value. We also performed a meta-analysis using...
random-effects models to combine the results of each replication of NHANES cycle in the validation set.

Continuous variables were expressed as the mean and SD (median and interquartile range, if a variable did not show normal distribution), and categorical variables were presented as frequencies with percentages. For chemicals measured in urine, creatinine-corrected concentrations were used to adjust the urinary dilution. For this purpose, all urinary chemical levels were divided by the urinary creatinine concentration. All variables were tested for normal distribution using the Kolmogorov–Smirnov test.

Most environmental chemical concentrations showed right-skewed distributions; therefore, they were log-transformed. All chemical concentrations were standardized to a mean of 0 and SD of 1 to compare their effect size.

R (version 3.5.2 for Windows) and SPSS software (version 21.0; IBM, Armonk, NY) were used for all analyses. A two-tailed P, 0.05 was considered significant.

Results

Participant Characteristics

A total of 46,748 adult participants were included in this analysis. Participant demographic and clinical characteristics are summarized in Table 1. The number of male participants was 25,709 (48%). Mean age of participants was 47±19 (range 18–85) years. Race/ethnicity of the included participants was 8979 (19%) Mexican American, 3771 (8%) Hispanic, 20,674 (44%) white, 9555 (20%) black, and 3769 (8%) other. Mean body mass index was 29±7 (range 12.0–130.2) kg/m², mean serum creatinine level was 0.89±0.37 mg/dl, median value of urinary ACR was 6.9 (interquartile range, 4.4–13.6) mg/g, and mean eGFR was 94±24 ml/min per 1.73 m². Hypertension and diabetes were prevalent in 39% and 13% of participants, respectively.

EWAS Analysis for CKD

The Manhattan plots of EWAS for CKD defined by the different criteria developed in the discovery set are presented in Figure 2. Seven (3%) chemicals were associated with increased prevalence of any of the three CKD outcomes, and 23 (9%) chemicals were associated with decreased prevalence of CKD. For albuminuria, four and one chemicals were associated with increased and decreased risk of CKD, respectively. For reduced eGFR, two and 22 chemicals were associated with increased and decreased risk of CKD, respectively. For composite CKD outcome, five and four chemicals were associated with increased and decreased risk of CKD, respectively.

Figure 2A shows the Manhattan plot of EWAS of albuminuria. Serum cotinine, urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanonol, blood cadmium, urinary cadmium, serum perfluorooctanoic acid, and eight blood volatile organic compounds were discovered. Among them, blood cadmium, serum cotinine, urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanonol, serum perfluorooctanoic acid, and blood 2,5-dimethylfuran were validated in the validation set. Those chemicals that showed significant associations with albuminuria are summarized in Table 2. Contrary to other discovered and validated chemicals, serum perfluorooctanoic acid was associated with a decreased risk of albuminuria.

Figure 2B shows the Manhattan plot of EWAS of reduced eGFR. Five urinary arsenics, two blood metals, seven
urinary metals, two perchlorates, two urinary phthalates (mono-benzyl and mono-carboxynonyl phthalates), three urinary polycyclic aromatic hydrocarbons, and six blood and six urinary volatile organic compounds were identified as significant factors in the discovery set. Among these, many chemicals were also identified as significant in the validation set, which included two blood metals (lead and cadmium), seven urinary metals (barium, cadmium, cobalt, cesium, molybdenum, lead, and thallium), three urinary arsenics (arsenocholine, arsenous acid, and arsenic acid), two urinary perchlorates (nitrate and thiocyanate), three urinary polycyclic aromatic hydrocarbons (1-phenanthrene, 2-phenanthrene, and 1-pyrene), and one blood and six urinary volatile organic compounds that showed associations of decreased prevalence of reduced eGFR.

Figure 2C shows the Manhattan plot of EWAS of composite CKD outcome. Serum cotinine, two blood metals (lead and cadmium), four urinary metals (barium, cesium, molybdenum, and thallium), serum perfluorooctane sulfonamide, urinary nitrate, one phthalate (mono-carboxynonyl phthalate), one urinary polycyclic aromatic hydrocarbon (2-fluorene), and seven blood and one urinary volatile organic compounds were discovered in the discovery set. Of these, validated environmental chemicals were two blood metals (lead and cadmium), three urinary metals (barium, cesium, and thallium), urinary nitrate, and two blood (2,5-dimethylfuran and furan) and one urinary volatile organic compound (phenylglyoxylic acid). Environmental chemicals that were significantly associated with composite CKD outcomes are shown in Table 4. Blood lead and cadmium and two blood (2,5-dimethylfuran and furan) and one urinary volatile organic compound (phenylglyoxylic acid) were associated with an increased risk of composite CKD outcome. Three urinary metals (barium, cesium, and thallium) and urinary nitrate

| Table 1. Characteristics of National Health and Nutrition Examination Survey (NHANES) participants included in an environment-wide association study |
|------------------------|-------------------|-----------------|
| Characteristic          | All Participants (n=46,748) | Discovery Set (n=25,281) | Validation Set (n=21,467) |
| Age, yr                 | 47 (19)           | 47 (19)         | 47 (19)          |
| Sex, male, %            | 22,656 (48)       | 12,295 (49)     | 10,361 (48)      |
| Body weight, kg         | 80 (21)           | 80 (21)         | 80 (21)          |
| Body mass index, kg/m²  | 29 (7)            | 28 (7)          | 29 (7)           |
| **Race/ethnicity, %**   |                   |                 |                 |
| Mexican American        | 8979 (19)         | 4867 (19)       | 4112 (19)        |
| Other Hispanic          | 3771 (8)          | 2307 (9)        | 1464 (7)         |
| Non-Hispanic white      | 20,674 (44)       | 10,544 (42)     | 10,130 (47)      |
| Non-Hispanic black      | 9555 (20)         | 5307 (21)       | 4248 (20)        |
| Other                   | 3769 (8)          | 2256 (9)        | 1513 (7)         |
| Diabetes mellitus, %    | 6094 (13)         | 3433 (14)       | 2661 (12)        |
| Hypertension, %         | 18,122 (39)       | 9985 (40)       | 8137 (38)        |
| Systolic BP, mm Hg (n=42,319) | 124 (20)   | 125 (20)        | 124 (19)         |
| Diastolic BP, mm Hg (n=42,319) | 70 (13)   | 70 (13)         | 70 (13)          |
| Fasting glucose, mg/dl  | 107 (36)          | 108 (38)        | 105 (33)         |
| Serum albumin, g/dl     | 4.2 (0.4)         | 4.3 (0.4)       | 4.2 (0.4)        |
| Uric acid, mg/dl        | 5.4 (1.5)         | 5.4 (1.5)       | 5.4 (1.5)        |
| BUN, mg/dl              | 13 (6)            | 13 (6)          | 13 (6)           |
| Serum creatinine, mg/dl | 0.89 (0.37)       | 0.89 (0.37)     | 0.90 (0.37)      |
| eGFR, ml/min per 1.73 m² | 94 (24)       | 94 (24)         | 94 (24)          |
| Urinary albumin-to-creatinine, mg/g¹ | 6.9 (4.4–13.6) | 7.0 (4.5–13.9) | 6.9 (4.4–13.2) |
| Cigarette smoking       |                   |                 |                 |
| Current smoker          | 9225 (20)         | 4894 (19)       | 4331 (20)        |
| Ex-smoker               | 10,801 (23)       | 5870 (23)       | 4931 (23)        |
| Never smoker            | 23,875 (51)       | 12,969 (51)     | 10,906 (51)      |
| Others (refused, do not know, missing) | 2847 (6)       | 1548 (6)        | 1299 (6)         |
| **Socioeconomic status** |                   |                 |                 |
| Family income-to-poverty ratio, family PIR (n=42,889) | 2.5 (1.6) | 2.5 (1.6) | 2.5 (1.6) |
| eGFR<60 ml/min per 1.73 m², % | 4315 (9)   | 2338 (9)        | 1977 (9)         |
| eGFR<45 ml/min per 1.73 m², % | 1509 (3)   | 816 (3)         | 693 (3)          |
| eGFR<30 ml/min per 1.73 m², % | 421 (1)    | 230 (1)         | 191 (1)          |
| ACR>30 mg/g, %          | 5642 (12)        | 3177 (13)       | 2465 (11)        |
| ACR>300 mg/g, %         | 958 (2)          | 554 (2)         | 404 (2)          |

Data are shown as mean and SD or numbers and proportion (%). PIR, poverty-income ratio; ACR, albumin-to-creatinine ratio. ¹Median (interquartile range).
were associated with decreased risk of composite CKD outcomes.

Blood cadmium consistently shows significant association with increased prevalence of CKD in all CKD definition criteria. Blood lead showed a significant association with increased prevalence of CKD in high degrees of albuminuria (Table 5). Moreover, the odds ratios increased gradually with the increase of albuminuria and decrease of eGFR. A combined effect of blood lead and cadmium was also shown in various CKD categories defined by albuminuria (Supplemental Table 1). Blood (2,5-dimethylfuran and furan) and urinary (phenylglyoxylic acid) volatile organic compounds were associated with an increased risk of CKD defined by albuminuria or eGFR (Table 4).
Increased blood 2,5-dimethylfuran levels were significantly associated with increased risk of CKD defined by low levels of albuminuria (urinary albumin-to-creatinine ratio $\geq 30$ mg/g) and CKD composite outcome (Supplemental Table 2).

Correlation between environmental chemicals are summarized with a correlation matrix (Supplemental Figures 1 and 2). Serum cotinine, urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), urine perchloroethylene, serum 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), urine perfluorooctanoic acid, and two volatile organic compounds (blood furan and 2,5-dimethylfuran) are highly correlated with each other among chemicals associated with increased risk of CKD. Urine arsenics and urine volatile organic compounds are highly correlated among chemicals associated with decreased CKD risk.

### Discussion

Our results, using the largest data set accumulated on the general United States population, clearly show that several chemicals exposed during daily lives are significantly associated with CKD. Among the 262 environmental chemicals, 30 (11%) chemicals were associated with any of the three CKD outcomes. Five (2%) chemicals were associated with albuminuria, 24 (9%) chemicals were associated with reduced eGFR, and nine (3%) chemicals were associated with albuminuria or eGFR.

A total of 262 chemicals were evaluated, and only those that met an FDR<1% in the discovery cohort and $P<0.05$ in the validation cohort are included in the table. Albuminuria is defined as urine albumin-to-creatinine ratio $\geq 30$ mg/g. Each chemical is evaluated per SD increment in log-transformed blood concentration or log-transformed chemical-to-creatinine ratio. 95% CI, 95% confidence interval; FDR, false discovery rate.

Volatile organic compounds (blood) were associated with decreased CKD risk. Increased blood 2,5-dimethylfuran levels were significantly associated with increased risk of CKD defined by low levels of albuminuria (urinary albumin-to-creatinine ratio $\geq 30$ mg/g) and CKD composite outcome (Supplemental Table 2).

Correlation between environmental chemicals are summarized with a correlation matrix (Supplemental Figures 1 and 2). Serum cotinine, urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), urine perchloroethylene, serum 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), urine perfluorooctanoic acid, and two volatile organic compounds (blood furan and 2,5-dimethylfuran) are highly correlated with each other among chemicals associated with increased risk of CKD. Urine arsenics and urine volatile organic compounds are highly correlated among chemicals associated with decreased CKD risk.

### Table 2. Chemicals significantly associated with albuminuria in an environment-wide association study

<table>
<thead>
<tr>
<th>Environmental Chemicals</th>
<th>Meta-Analysis (Discovery Data Set)</th>
<th>Meta-Analysis (Validation Data Set)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Odds Ratio (95% CI)</td>
<td>FDR</td>
</tr>
<tr>
<td>Metal (blood)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cadmium</td>
<td>1.28 (1.20 to 1.36)</td>
<td>$6.28 \times 10^{-11}$</td>
</tr>
<tr>
<td>Cotinines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cotinine, serum</td>
<td>1.17 (1.09 to 1.25)</td>
<td>$2.55 \times 10^{-4}$</td>
</tr>
<tr>
<td>Nitrosamine metabolite</td>
<td>1.21 (1.10 to 1.34)</td>
<td>$5.00 \times 10^{-3}$</td>
</tr>
<tr>
<td>Perfluorooctanoic acid, serum</td>
<td>0.69 (0.57 to 0.83)</td>
<td>$3.05 \times 10^{-3}$</td>
</tr>
<tr>
<td>Volatile organic compounds (blood)</td>
<td>1.26 (1.11 to 1.42)</td>
<td>$5.52 \times 10^{-3}$</td>
</tr>
</tbody>
</table>

A total of 262 chemicals were evaluated, and only those that met an FDR<1% in the discovery cohort and $P<0.05$ in the validation cohort are included in the table. Albuminuria is defined as urine albumin-to-creatinine ratio $\geq 30$ mg/g. Each chemical is evaluated per SD increment in log-transformed blood concentration or log-transformed chemical-to-creatinine ratio. 95% CI, 95% confidence interval; FDR, false discovery rate.
associated with the decreased prevalence of CKD defined by various range of albuminuria and lowest eGFR criteria (Supplemental Table 3). To date, no study has reported significant association between perfluorooctanoic acid levels and albuminuria in humans. This is an interesting observation because, in earlier NHANES, elevated serum perfluorooctanoic acid levels were associated with CKD on the basis of eGFR (43). Indeed, several epidemiologic studies have reported its association with decreased eGFR (44), although U-shaped association between polyfluoroalkyl substances and eGFR has also been reported (45). However, studies suggesting potential reverse causation, possibly owing to reduced kidney function, are accumulating. Polyfluoroalkyl substance concentrations were associated with decreased eGFR in people without CKD; however, these were associated with increased eGFR among patients with CKD (46). In addition, menopausal status can affect serum polyfluoroalkyl substance concentration, as menstruation is a well known excretion route of polyfluoroalkyl substance among women (47). Among adult women, it was reported that earlier menopause and reduced kidney function were the causes rather than the results of increased measured serum perfluorooctanoic acid (48). Seafood consumption may increase serum perfluorooctanoic acid levels (49,50) and should also be carefully controlled as a confounder of the causal relationship, because fish provides polyunsaturated fatty acids that are beneficial for preventing chronic diseases, including cardiovascular disease (51–53). Therefore, the association between perfluorooctanoic acid and decreased CKD prevalence observed in the present population warrants further investigation with a more refined analytical design, e.g., inclusion of perfluorooctanoic acid–specific confounders in the model.

Previous studies reported associations between urinary excretion of heavy metals and increased eGFR (54–60). Jin et al. (61) observed similar findings among the 11 metals (cadmium, lead, mercury, total arsenic, dimethylnitrosamine acid, barium, cobalt, cesium, molybdenum, thallium, and tungsten), and urinary excretion rates of lead and cadmium decreased according to the decrease of eGFR at a similar blood lead or cadmium concentration status. These associations between urinary concentrations of heavy metals and eGFR might result from the decreased urinary excretion of chemicals in CKD patients with decreased eGFR (62,63).

Although this study used the largest number of participants, with hundreds of chemicals in consideration, as a
among the chemicals, in terms of toxicological modes of action and commonality of the exposure sources, could not be reflected and may lead to false negative or positive associations.

Our findings suggest that increased exposure to heavy metal lead, cadmium, or volatile organic compounds can be associated with increased prevalence of CKD. For each chemical that showed significant associations with CKD,
further studies that investigate the pathophysiologic mechanisms of nephrotoxicity of these environmental chemicals, using in vitro or in vivo experimental models, and that validate the association of exposure to the environmental chemicals and CKD in other populations are warranted. Prospective, longitudinal, cohort studies with multiple repetitive sampling could help to support the causality of the observed relationship.

Acknowledgments
The authors would like to thank the study participants.

Disclosures
All authors have nothing to disclose.

Funding
This work was supported by the Seoul Metropolitan Government Seoul National University Boramae Medical Center (clinical research grant-in-aid 03-2019-25) and the Korean Society of Nephrology grant in 2018 (BAXTER).

Supplemental Material
This article contains the following supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.06780619/-/DCSupplemental.

Supplemental Table 1. Interaction of blood lead and cadmium with the risk of CKD in whole data set according to the degree of albuminuria, eGFR, and composite categories.

Supplemental Table 2. Blood 2,3-dimethylfurran and CKD: meta-analysis results from discovery data set and validation data set according to the degree of albuminuria, eGFR, and composite categories.

Supplemental Table 3. Serum perfluorooctanoic acid and CKD: meta-analysis results from discovery data set and validation data set according to the degree of albuminuria, eGFR, and composite categories.

Supplemental Figure 1. Correlation matrix between environmental chemicals associated with increased risk of CKD.

Supplemental Figure 2. Correlation matrix between environmental chemicals associated with decreased risk of CKD.

Supplemental Appendix 1. Measurement of chemicals.

Supplemental Appendix 2. Sample weights.

Supplemental Appendix 3. List of chemicals.

References


Received: June 11, 2019 Accepted: February 23, 2020

J.L. and S.O. contributed equally to this work.

Published online ahead of print. Publication date available at www.cjasn.org.